A Double-Masked, Placebo-Controlled, Randomized,Phase II Clinical Trial ToAssess The Efficacy Of IVIEW-1201 In The Treatment Of Acute Adenoviral ConjunctivitisClinical Efficacy and Safety of IVIEW-1201 (1.0% PVP-Iodine) Gel FormingOphthalmic Solution Compared to Placebo in the Treatment of AdenoviralConjunctivitis

开始日期2023-01-16

申办/合作机构

IVIEW Therapeutics, Inc.初创企业

NCT03749317 / Completed临床2期

A Double-Masked, Placebo-Controlled, Randomized, Phase II Clinical Trial To Assess The Efficacy Of IVIEW-1201 In The Treatment Of Acute Adenoviral Conjunctivitis

A Phase 2, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of IVIEW-1201 (1.0% Povidone-Iodine) Gel Forming Ophthalmic Solution Compared to Placebo in the Treatment of Adenoviral Conjunctivitis

开始日期2019-12-19

申办/合作机构

IVIEW Therapeutics, Inc.初创企业

CTRI/2019/07/020282 / Terminated临床2期

A Double-Masked, Placebo-Controlled, Randomized,Phase II Clinical Trial To Assess The Efficacy Of IVIEW-1201 in the Treatment of Acute Adenoviral Conjunctivitis

开始日期2019-10-04

申办/合作机构

IVIEW Therapeutics, Inc.初创企业

100 项与腺病毒性结膜炎相关的临床结果

登录后查看更多信息

100 项与腺病毒性结膜炎相关的转化医学

登录后查看更多信息

0 项与腺病毒性结膜炎相关的专利（医药）

登录后查看更多信息

218

项与腺病毒性结膜炎相关的文献（医药）

2024-12-01·Journal Français d'Ophtalmologie

Conjonctivites virales et chlamydiennes

Review

作者: Loukil, M. ; Labetoulle, M ; Loukil, M ; Barreau, E. ; Labetoulle, M. ; Zina, S ; Resnikoff, S ; Rousseau, A. ; Vauloup-Fellous, C ; Bouvet, M. ; Barreau, E ; Zina, S. ; Bouvet, M ; Rousseau, A ; Vauloup-Fellous, C. ; Benali, M. ; Benali, M ; Resnikoff, S.

Viral conjunctivitis is the most common type of conjunctivitis. It is contagious and is predominantly seen as adenovirus-related conjunctivitis and keratoconjunctivitis (ADV). These infections are the most frequent ocular surface infections and can lead to conjunctival scarring and corneal opacities. Other types of viral conjunctivitis are often secondary to systemic infection and typically resolve spontaneously. Chlamydial conjunctivitis, on the other hand, is dominated by trachoma, which remains endemic in 42 countries and is still the leading cause of infectious blindness worldwide. In industrialized countries, chlamydia can also cause neonatal conjunctivitis and sometimes chronic conjunctivitis, occasionally associated with sexually transmitted diseases. This comprehensive review provides clinicians with essential microbiological, epidemiological, clinical, and therapeutic data on these two major groups of infectious conjunctivitis.

2024-08-01·eJHaem

Overcoming post‐transplant graft failure and adenovirus infection in a patient with FLT3‐TKD‐mutated mixed‐phenotype acute leukemia: A case report

Article

作者: Okubo, So ; Yamaguchi, Hiroki ; Hirahara, Ayumi ; Ito, Chisako ; Aisa, Yoshinobu ; Hibi, Masaki ; Ueki, Toshimitsu ; Wakita, Satoshi ; Yokota, Takako ; Najima, Yuho ; Masuda, Moe ; Yoshida, Tsutomu ; Takada, Yusuke ; Kurosawa, Shuhei ; Sakurai, Aki ; Nakayama, Hitomi ; Nakazato, Tomonori

AbstractMixed‐phenotype acute leukemia (MPAL) with FLT3‐TKD mutations is a rare and challenging subtype of leukemia. Effective management strategies are crucial for improving patient outcomes. A 31‐year‐old man with FLT3‐TKD‐mutated MPAL achieved hematological remission through the JALSG ALL202‐O protocol and gilteritinib, followed by cord blood transplantation (CBT). Post‐transplant complications included adenovirus‐induced hemorrhagic cystitis, managed with bladder irrigation and ribavirin, and engraftment failure, necessitating a second CBT on Day 35. Subsequent adenoviral conjunctivitis resolved with vidarabine. The patient achieved neutrophil engraftment by Day 76 and was discharged on Day 173 without relapse. This case highlights the importance of vigilant supportive care and tailored therapy in managing MPAL with FLT3 mutations, especially in the context of post‐transplant complications.

2024-04-01·Contact Lens and Anterior Eye

Natural history of adenoviral conjunctivitis in a US-based population: Viral load, signs, and symptoms

Article

作者: Harthan, Jennifer S ; Johnson, Spencer D ; Olson, Christian K ; Morettin, Christina E ; Hartwick, Andrew T E ; Shorter, Ellen ; Gordon, Mae O ; Than, Tammy ; Huecker, Julia B ; Whiteside, Meredith ; Migneco, Mary K ; Alferez, Christopher S ; van Zyl, Tavé

PURPOSETo report the clinical signs, symptoms, and viral clearance in individuals in the United States with adenoviral conjunctivitis (Ad-Cs).METHODSIndividuals ≥ 18 years presenting within 4 days of symptoms of Ad-Cs who met eligibility criteria and tested positive with both point-of-care immunoassay antigen and quantitative polymerase chain reaction (qPCR) testing were enrolled. Patient-reported symptoms, clinician-graded signs, and qPCR viral titers were collected at baseline, days 1-2, 4 (days 3-5), 7 (days 6-10), 14 (days 11-17) and 21 (days 18-21).RESULTSThere was no detectable viral titers by the day 14 visit in 6/8 patients. By day 21, there was no detectable viral titers in the 7 participants who completed the visit; however, signs and symptoms persisted including: blurry vision (5/7), discomfort (2/7) or redness (1/7). Masked clinicians also noted conjunctival redness (4/7), follicular conjunctivitis (4/7) and bulbar edema (3/7).CONCLUSIONMany patient-reported symptoms and clinical signs persist after viral titers are no longer detectable by qPCR. Using clinical signs and symptoms to determine quarantine duration may result in patients being furloughed longer than the time that the patient is infectious.